What Dimension Inx does

Dimension Bio (formerly Dimension Inx) is a Chicago-based, venture-backed regenerative therapeutics company founded in 2017 that designs, develops, and manufactures 3D-printed biomaterial scaffolds intended to direct tissue regeneration and healing. Its foundational technology is the BioNidum platform, a bioinspired system that fuses materials science, 3D printing, and digital manufacturing to engineer regenerative microenvironments with independent control of material composition, three-dimensional architecture, and microstructure. The platform underpins multiple proprietary material families, including the Hyperelastic Bone composite (hydroxyapatite particles in a biodegradable PLG polymer), the Fluffy-X highly tunable porous material family, and the Tissue Papers decellularized ECM-based material family, supported by issued U.S. patents and proprietary manufacturing know-how rooted in nearly a decade of research at Northwestern University's Tissue Engineering and Additive Manufacturing Lab.

The company's commercial lead asset is CMFlex, the first FDA 510(k)-cleared 3D-printed regenerative bone graft (cleared December 2022), positioned as a ready-to-use flexible ceramic for oral and maxillofacial bone reconstruction. Revenue mechanics span three streams: (1) product sales of CMFlex to healthcare institutions via direct enterprise sales engagement with oral/maxillofacial, plastic/reconstructive, dental, and orthopedic surgeons, with an initial limited release to key opinion leader surgeons followed by broader commercial rollout; (2) biotech partner collaborations structured as professional services or co-development arrangements for biomaterial and regenerative product challenges; and (3) internal therapeutic product development targeting high-unmet-need indications including liver failure and Type 1 diabetes via BioNidum-based cell delivery scaffolds, with future licensing and royalty potential. Through November 2025 the company has raised approximately $17.8M in cumulative funding across seed, government, and Series A rounds, with a 11-50 employee headcount and an explicit strategic emphasis on scaling manufacturing and clinical development beyond the initial bone graft indication.

Name

Dimension Inx

Legal name

Dimension Inx Corp.

Website

https://dimensioninx.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Regenerative Medicine / Tissue Engineering Medical Devices

NAICS

Dental Laboratories (339116)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials) (HLAAAGAB)

akta.pro secondary industries

Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG), 3D Bioprinting & Biofabrication (HLAAAGAC), Medical Devices & Dental (Production AM Parts) (IMAAAEAD)

Keywords

• Regenerative therapeutics
• 3D-printed bone grafts
• Biomaterials platform
• Tissue engineering
• Medical device manufacturing

Headquarters

HQ city

Chicago

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Product Sales - CMFlex: Sale of FDA-cleared 3D-printed regenerative bone graft product CMFlex for oral and maxillofacial surgical applications. Initially targeting key surgeons with broader commercial release planned.
2. Biotech Partner Collaborations: Working shoulder-to-shoulder with biotech partners to solve challenging materials problems, including co-development of regenerative products for therapeutic applications.
3. Internal Therapeutic Product Development: Internally developing regenerative products for therapeutic applications with high unmet clinical need including organ restoration, cell therapies for liver failure and type 1 diabetes.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Dimension Inx designs, develops, and manufactures regenerative biomaterial products on its proprietary BioNidum platform, which fuses materials science, 3D printing, and digital manufacturing to engineer microenvironments that drive tissue healing. Its commercial lead product is CMFlex, the first FDA-cleared 3D-printed regenerative bone graft for oral and maxillofacial applications. The company also licenses its platform for internal therapeutic product development (cell therapies for liver failure and Type 1 diabetes) and co-develops regenerative products with biotech partners.

Product overview

Dimension Bio (formerly Dimension Inx) operates a platform-based business model centered on its BioNidum™ platform, which serves as the foundation for developing implantable and injectable biosynthetic products for regenerative therapeutics. The company develops products both internally and in partnership with biotech companies. The commercial product portfolio includes CMFlex™ (FDA-cleared 3D-printed regenerative bone graft), while material technology families include Fluffy-X™ (porous tunable materials) and Tissue Papers™ (decellularized ECM materials), all built on the proprietary Hyperelastic Bone® composite technology.

Differentiator

Problem solved

Functional benefit

Brands

• CMFlex: First 3D-printed regenerative bone graft product cleared by the FDA, a ready-to-use flexible ceramic graft for oral and maxillofacial indications.
• BioNidum
• Fluffy-X
• Tissue Papers
• Hyperelastic Bone

Products and services

• CMFlex CMFlex is the first FDA-cleared 3D-printed regenerative bone graft, a ready-to-use flexible ceramic graft for oral and maxillofacial bone reconstruction. It uses Dimension Bio's proprietary Hyperelastic Bone composite material of hydroxyapatite particles and PLG polymer, with fluid absorption capability for hemostasis, bone remodeling, and tissue integration.
• BioNidum Platform BioNidum is Dimension Bio's bioinspired platform that fuses materials science, 3D printing, and digital manufacturing to engineer regenerative microenvironments that influence cell behavior, tissue organization, and healing. It provides independent control of material composition, 3D architecture, and microstructure, supporting development of implantable and injectable biosynthetic products tailored to different tissues and clinical applications.
• Fluffy-X Material Family Fluffy-X is a highly tunable and porous biomaterial family covered by U.S. Patent No. 11,896,740, developed from nearly a decade of research at Northwestern University. It offers excellent handling properties and mechanical integrity for regenerative applications.
• Tissue Papers Material Family Tissue Papers is a decellularized ECM-based biomaterial family covered by U.S. Patent No. 11,904,071, providing control of both material structure and composition for advanced tissue repair constructs and cell delivery applications.
• Hyperelastic Bone (composite material technology) Hyperelastic Bone is a proprietary microstructurally porous composite material comprised of hydroxyapatite particles combined with biodegradable polylactide-co-glycolide (PLG) polymer. It is 3D-printable and forms the base of the CMFlex bone graft product.

Quantifiable outcome

• First 3D-printed regenerative bone graft product cleared by FDA
• +1 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Northwestern UniversitycoreStrategic or Co-development PartnerCo-founders Ramille Shah and Adam Jakus developed core technologies from nearly a decade of research at Northwestern University's Tissue Engineering and Additive Manufacturing Lab. Ongoing research relationship.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Integra LifeSciences: Integra LifeSciences is a large medical device company with a substantial regenerative technologies portfolio (e.g., Integra Dermal Regeneration Template, bone graft substitutes). Comparable to Dimension Bio as a broad incumbent in regenerative medicine with overlapping product categories in wound/skin regeneration and bone repair, though it serves a much wider portfolio of indications.
• Organogenesis: Organogenesis is a commercial-stage regenerative medicine company focused on wound care and surgical biologics (Apligraf, Dermagraft, PuraPly). Comparable as a public regenerative medicine company selling FDA-approved biomaterial products to surgeons and hospitals, though it focuses primarily on wound/skin applications rather than bone.
• Stryker (Orthobiologics): Stryker is a global medical device leader with a substantial orthobiologics portfolio including bone graft substitutes (Vitoss, OP-1) and regenerative materials for spine, orthopedic, and CMF applications. Comparable as a broad incumbent in the bone graft substitute market Dimension Bio targets with CMFlex, though with much broader product breadth and established sales channels.

Direct peers

• Xtant Medical: Xtant Medical is a pure-play orthobiologics company focused on bone graft substitutes and sports medicine applications. Directly comparable to Dimension Bio's CMFlex in the bone graft substitute market, with overlapping surgeon customers (spine, orthopedic) and a similar product-led commercial model.
• LifeNet Health: LifeNet Health is a leading allograft and regenerative medicine nonprofit, providing bone, soft tissue, and cellular allograft products for surgical use. Comparable to Dimension Bio as a regenerative medicine company serving oral/maxillofacial, orthopedic, and spine surgeons with bone and tissue graft products, although LifeNet primarily uses allograft (donor tissue) versus Dimension Bio's synthetic 3D-printed approach.
• MTF Biologics: MTF Biologics is a nonprofit tissue bank supplying allograft bone grafts, sports medicine grafts, and wound care allografts. Directly comparable to Dimension Bio in the bone graft substitute and regenerative medicine market, serving overlapping surgical specialties with musculoskeletal focus.
• NovaBone Products: NovaBone Products manufactures synthetic bone graft substitutes (calcium phosphosilicate-based) for dental, oral/maxillofacial, and orthopedic applications. Directly comparable to Dimension Bio's CMFlex as a synthetic bone graft competitor targeting oral surgeons and dental implant specialists.
• MiMedx: MiMedx develops and commercializes regenerative biologics using placental tissue allografts for wound care, surgical recovery, and musculoskeletal applications. Comparable to Dimension Bio as a regenerative medicine company selling biomaterial-based products to surgeons, though it uses placental tissue rather than 3D-printed synthetic constructs.

Emerging players

• Vericel: Vericel develops advanced cell therapies and specialty biologics for the sports medicine and severe burn care markets (MACI, Epicel). Comparable to Dimension Bio as a regenerative medicine company with surgical/orthopedic applications and a cell therapy pipeline, though at a more advanced commercial stage.
• Organovo: Organovo is a 3D bioprinting company developing functional human tissues for therapeutic applications and research use. Comparable to Dimension Bio as an emerging player in 3D bioprinting and tissue engineering, though Organovo is focused on liver tissue for research/drug testing rather than surgical implant applications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds5 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dimension Inx